Maxim analyst Jason McCarthy downgraded Synaptogenix to Hold from Buy.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SNPX:
- Synaptogenix Plunges 75% after Disappointing Trial Data
- Synaptogenix announces results from Phase 2 clinical trial of Bryostatin-1
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue